Chemokines: agents for the immunotherapy of cancer?
- 1 March 2002
- journal article
- review article
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 2 (3), 175-184
- https://doi.org/10.1038/nri748
Abstract
Chemokines, a superfamily of small cytokine-like molecules, regulate leukocyte transport in the body. In recent years, we have witnessed the transition of immunotherapeutic strategies from the laboratory to the bedside. Here, we review the role of chemokines in tumour biology and the development of the host's anti-tumour defence. We summarize the current knowledge of chemokine-receptor expression by relevant cellular components of the immune system and the role of their ligands in the organization of the antitumour immune response. Finally, we discuss recent findings which indicate that chemokines have therapeutic potential as adjuvants or treatments in antitumour immunotherapy, as well as remaining questions and perspectives for translating experimental evidence into clinical practice.Keywords
This publication has 79 references indexed in Scilit:
- Rapid Acquisition of Tissue-specific Homing Phenotypes by CD4+ T Cells Activated in Cutaneous or Mucosal Lymphoid TissuesThe Journal of Experimental Medicine, 2002
- Surrogate markers of response to cancer immunotherapyExpert Opinion on Biological Therapy, 2001
- Regulatable systems: applications in gene therapy and replicating virusesJournal of Clinical Investigation, 2000
- CCR7 Ligands, SLC/6Ckine/Exodus2/TCA4 and CKβ-11/MIP-3β/ELC, Are Chemoattractants for CD56+CD16−NK Cells and Late Stage Lymphoid ProgenitorsCellular Immunology, 1999
- Adenoviral Vectors Expressing Lymphotactin and Interleukin 2 or Lymphotactin and Interleukin 12 Synergize to Facilitate Tumor Regression in Murine Breast Cancer ModelsHuman Gene Therapy, 1999
- A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cellsEuropean Journal of Immunology, 1998
- The CXC Chemokines Growth-regulated Oncogene (GRO) α, GROβ, GROγ, Neutrophil-activating Peptide-2, and Epithelial Cell-derived Neutrophil-activating Peptide-78 Are Potent Agonists for the Type B, but Not the Type A, Human Interleukin-8 ReceptorJournal of Biological Chemistry, 1996
- Lymphocyte Homing and HomeostasisScience, 1996
- The Functional Role of the ELR Motif in CXC Chemokine-mediated AngiogenesisJournal of Biological Chemistry, 1995
- Interleukin-2 in cancer treatment: Disappointing or (still) promising? A reviewCancer Immunology, Immunotherapy, 1993